Colorectal cancer statistics, 2014

CA Cancer Journal for Clinicians

Volumn 64, Issue 2, 2014, Pages 104-117

  Siegel, Rebecca ^a   Desantis, Carol ^a   Jemal, Ahmedin ^a  

^a AMERICAN CANCER SOCIETY   (United States)

Author keywords

Colon and rectum neoplasms; Epidemiology; Health disparities; Screening and early detection

Indexed keywords

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; ASCENDING COLON; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER MORTALITY; CANCER SCREENING; CANCER STATISTICS; CANCER SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; ETHNICITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NATIONAL HEALTH ORGANIZATION; ONSET AGE; PRIORITY JOURNAL; SEX RATIO; TREND STUDY; TUMOR LOCALIZATION; VERY ELDERLY;

COLON AND RECTUM NEOPLASMS; EPIDEMIOLOGY; HEALTH DISPARITIES; SCREENING AND EARLY DETECTION;

ADULT; AGED; AGED, 80 AND OVER; CENTERS FOR DISEASE CONTROL AND PREVENTION (U.S.); COLORECTAL NEOPLASMS; CONTINENTAL POPULATION GROUPS; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; REGISTRIES; RISK FACTORS; SEER PROGRAM; SURVIVAL ANALYSIS; UNITED STATES;

EID: 84899438176     PISSN: 00079235     EISSN: 15424863     Source Type: Journal    
DOI: 10.3322/caac.21220     Document Type: Article

References (80)

1. Siegel R, Ma J, Zhaohui Z, Jemal A,. Cancer statistics, 2014. CA Cancer J Clin. 2014; 64: 9-29.
2. Vogelaar I, van Ballegooijen M, Schrag D, et al. How much can current interventions reduce colorectal cancer mortality in the U.S. Mortality projections for scenarios of risk-factor modification, screening, and treatment. Cancer. 2006; 107: 1624-1633.
3. Surveillance, Epidemiology, and End Results (SEER) Program. SEERStat Database: Mortality-All COD, Aggregated With State, Total US (1969-2010) . Bethesda, MD: National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program, Cancer Statistics Branch; 2013. Released April 2013; underlying mortality data provided by National Center for Health Statistics, 2013.
4. Surveillance, Epidemiology, and End Results (SEER) Program. SEERStat Database: Incidence-SEER 9 Regs Public Use, Nov. 2011 Sub (1973-2010)-Linked to County Attributes-Total US, 1969-2011 Counties. Bethesda, MD: National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program, Cancer Statistics Branch; 2013.
5. Surveillance, Epidemiology, and End Results (SEER) Program. SEERStat Database: Incidence-SEER 13 Regs Public Use, Nov. 2011 Sub (1992-2010)-Linked to County Attributes-Total US, 1969-2011 Counties. Bethesda, MD: National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program, Cancer Statistics Branch; 2013.
6. Surveillance, Epidemiology, and End Results (SEER) Program. SEERStat Database: Incidence-SEER 18 Regs Public Use, Nov. 2012 Sub (2000-2010)-Linked to County Attributes-Total US, 1969-2011 Counties. Bethesda, MD: National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program, Cancer Statistics Branch; 2013.
7. Surveillance, Epidemiology, and End Results (SEER) Program SEERStat Database: North American Association of Central Cancer Registries (NAACCR) Incidence-CiNA Analytic File, 1995-2010, for Expanded Races, custom file with county, ACS Facts & Figures projection project, North American Association of Central Cancer Registries. Bethesda, MD: National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program, Cancer Statistics Branch; 2013.
8. Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion. 2012 Behavioral Risk Factor Surveillance System (BRFSS) Public Use Data Tapes. Atlanta, GA: Centers for Disease Control and Prevention; 2013.
9. Centers for Disease Control and Prevention (CDC). Methodologic changes in the Behavioral Risk Factor Surveillance System in 2011 and potential effects on prevalence estimates. MMWR Morb Mortal Wkly Rep. 2012; 61: 410-413.
10. National Center for Health Statistics, Division of Health Interview Statistics, Centers for Disease Control and Prevention. National Health Interview Survey Public Use Data File 2010. Hyattsville, MD: National Center for Health Statistics; 2011.
11. Chen HS, Portier K, Ghosh K, et al. Predicting US- and state-level cancer counts for the current calendar year: Part I: evaluation of temporal projection methods for mortality. Cancer. 2012; 118: 1091-1099.
12. Zhu L, Pickle LW, Ghosh K, et al. Predicting US- and state-level cancer counts for the current calendar year: Part II: evaluation of spatiotemporal projection methods for incidence. Cancer. 2012; 118: 1100-1109.
13. Fritz A, Percy C, Jack A, et al, eds. International Classification of Diseases for Oncology. 3rd ed. Geneva: World Health Organization; 2000.
14. Surveillance Research Program, National Cancer Institute. SEERStat software. Version 8.1.2. Bethesda, MD: National Cancer Institute; 2013.
15. Clegg LX, Feuer EJ, Midthune DN, Fay MP, Hankey BF,. Impact of reporting delay and reporting error on cancer incidence rates and trends. J Natl Cancer Inst. 2002; 94: 1537-1545.
16. DevCan: Probability of Developing or Dying of Cancer Software. Version 6.7.0. Bethesda, MD: Statistical Research and Applications Branch, National Cancer Institute; 2005.
17. Murphy G, Devesa SS, Cross AJ, Inskip PD, McGlynn KA, Cook MB,. Sex disparities in colorectal cancer incidence by anatomic subsite, race and age. Int J Cancer. 2011; 128: 1668-1675.
18. Meissner HI, Breen N, Klabunde CN, Vernon SW,. Patterns of colorectal cancer screening uptake among men and women in the United States. Cancer Epidemiol Biomarkers Prev. 2006; 15: 389-394.
19. DeNavas-Walt C, Proctor BD, Smith JC,; US Census Bureau. Current Population Reports: Income, Poverty, and Health Insurance Coverage in the United States: 2012. P60-245. Washington, DC: US Government Printing Office; 2013.
20. Albano JD, Ward E, Jemal A, et al. Cancer mortality in the United States by education level and race. J Natl Cancer Inst. 2007; 99: 1384-1394.
21. Doubeni CA, Laiyemo AO, Major JM, et al. Socioeconomic status and the risk of colorectal cancer: an analysis of more than a half million adults in the National Institutes of Health-AARP Diet and Health Study. Cancer. 2012; 118: 3636-3644.
22. Doubeni CA, Major JM, Laiyemo AO, et al. Contribution of behavioral risk factors and obesity to socioeconomic differences in colorectal cancer incidence. J Natl Cancer Inst. 2012; 104: 1353-1362.
23. Chu KC, Miller BA, Springfield SA,. Measures of racial/ethnic health disparities in cancer mortality rates and the influence of socioeconomic status. J Natl Med Assoc. 2007; 99: 1092-1100, 1102-1104.
24. Pinheiro PS, Sherman RL, Trapido EJ, et al. Cancer incidence in first generation U.S. Hispanics: Cubans, Mexicans, Puerto Ricans, and new Latinos. Cancer Epidemiol Biomarkers Prev. 2009; 18: 2162-2169.
25. Kamangar F, Dores GM, Anderson WF,. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006; 24: 2137-2150.
26. Iacopetta B,. Are there two sides to colorectal cancer? Int J Cancer. 2002; 101: 403-408.
27. Matanoski G, Tao X, Almon L, Adade AA, Davies-Cole JO,. Demographics and tumor characteristics of colorectal cancers in the United States, 1998-2001. Cancer. 2006; 107 (suppl 5): 1112-1120.
28. Nawa T, Kato J, Kawamoto H, et al. Differences between right- and left-sided colon cancer in patient characteristics, cancer morphology and histology. J Gastroenterol Hepatol. 2008; 23: 418-423.
29. Howlader N, Noone AM, Krapcho M, et al. eds. SEER Cancer Statistics Review, 1975-2010. Bethesda, MD: National Cancer Institute; 2013.
30. Bach PB, Schrag D, Brawley OW, Galaznik A, Yakren S, Begg CB,. Survival of blacks and whites after a cancer diagnosis. JAMA. 2002; 287: 2106-2113.
31. Edwards BK, Noone A, Boscoe F, et al. Annual report to the nation on the status of cancer, 1975-2010, featuring comorbidity prevalence and impact on survival among persons with lung, colorectal, breast, or prostate cancer. Cancer [published online ahead of print December 16, 2013].
32. Le H, Ziogas, A, Lipkin, SM, Zell, JA,. Effects of socioeconomic status and treatment disparities in colorectal cancer survival. Cancer Epidemiol Biomarkers Prev. 2008; 17: 1950-1962.
33. Ward E, Jemal A, Cokkinides V, et al. Cancer disparities by race/ethnicity and socioeconomic status. CA Cancer J Clin. 2004; 54: 78-93.
34. Ayanian JZ, Zaslavsky AM, Fuchs CS, et al. Use of adjuvant chemotherapy and radiation therapy for colorectal cancer in a population-based cohort. J Clin Oncol. 2003; 21: 1293-1300.
35. Butler EN, Chawla N, Lund J, Harlan LC, Warren JL, Yabroff KR,. Patterns of colorectal cancer care in the United States and Canada: a systematic review. J Natl Cancer Inst Monogr. 2013; 2013: 13-35.
36. Du XL, Fang S, Vernon SW, et al. Racial disparities and socioeconomic status in association with survival in a large population-based cohort of elderly patients with colon cancer. Cancer. 2007; 110: 660-669.
37. Gross CP, Smith BD, Wolf E, Andersen M,. Racial disparities in cancer therapy: did the gap narrow between 1992 and 2002? Cancer. 2008; 112: 900-908.
38. Potosky AL, Harlan LC, Kaplan RS, Johnson KA, Lynch CF,. Age, sex, and racial differences in the use of standard adjuvant therapy for colorectal cancer. J Clin Oncol. 2002; 20: 1192-1202.
39. Jessup JM, Stewart A, Greene FL, Minsky BD,. Adjuvant chemotherapy for stage III colon cancer: implications of race/ethnicity, age, and differentiation. JAMA. 2005; 294: 2703-2711.
40. McCollum AD, Catalano PJ, Haller DG, et al. Outcomes and toxicity in African-American and Caucasian patients in a randomized adjuvant chemotherapy trial for colon cancer. J Natl Cancer Inst. 2002; 94: 1160-1167.
41. Simpson DR, Martinez ME, Gupta S, et al. Racial disparity in consultation, treatment, and the impact on survival in metastatic colorectal cancer. J Natl Cancer Inst. 2013; 105: 1814-1820.
42. Andaya AA, Enewold L, Zahm SH, et al. Race and colon cancer survival in an equal-access health care system. Cancer Epidemiol Biomarkers Prev. 2013; 22: 1030-1036.
43. Mason JB, Dickstein A, Jacques PF, et al. A temporal association between folic acid fortification and an increase in colorectal cancer rates may be illuminating important biological principles: a hypothesis. Cancer Epidemiol Biomarkers Prev. 2007; 16: 1325-1329.
44. Pfeiffer CM, Caudill SP, Gunter EW, Osterloh J, Sampson EJ,. Biochemical indicators of B vitamin status in the US population after folic acid fortification: results from the National Health and Nutrition Examination Survey 1999-2000. Am J Clin Nutr. 2005; 82: 442-450.
45. Cole BF, Baron JA, Sandler RS, et al. Folic acid for the prevention of colorectal adenomas: a randomized clinical trial. JAMA. 2007; 297: 2351-2359.
46. Song J, Medline A, Mason JB, Gallinger S, Kim YI,. Effects of dietary folate on intestinal tumorigenesis in the apcMin mouse. Cancer Res. 2000; 60: 5434-5440.
47. Sanjoaquin MA, Allen N, Couto E, Roddam AW, Key TJ,. Folate intake and colorectal cancer risk: a meta-analytical approach. Int J Cancer. 2005; 113: 825-828.
48. Stevens VL, McCullough ML, Sun J, Jacobs EJ, Campbell PT, Gapstur SM,. High levels of folate from supplements and fortification are not associated with increased risk of colorectal cancer. Gastroenterology. 2011; 141: 98-105, 105.e1.
49. Larsen IK, Bray F,. Trends in colorectal cancer incidence in Norway 1962-2006: an interpretation of the temporal patterns by anatomic subsite. Int J Cancer. 2010; 126: 721-732.
50. Hubbard JM, Grothey A,. Adolescent and young adult colorectal cancer. J Natl Compr Canc Netw. 2013; 11: 1219-1225.
51. Siegel RL, Jemal A, Ward EM,. Increase in incidence of colorectal cancer among young men and women in the United States. Cancer Epidemiol Biomarkers Prev. 2009; 18: 1695-1698.
52. Aleksandrova K, Pischon T, Buijsse B, et al. Adult weight change and risk of colorectal cancer in the European Prospective Investigation into Cancer and Nutrition. Eur J Cancer. 2013; 49: 3526-3536.
53. Larsson SC, Wolk A,. Obesity and colon and rectal cancer risk: a meta-analysis of prospective studies. Am J Clin Nutr. 2007; 86: 556-565.
54. Levi Z, Kark JD, Barchana M, et al. Measured body mass index in adolescence and the incidence of colorectal cancer in a cohort of 1.1 million males. Cancer Epidemiol Biomarkers Prev. 2011; 20: 2524-2531.
55. National Center for Health Statistics. Health, United States, 2012: With Special Feature on Emergency Care. Hyattsville, MD: National Center for Health Statistics; 2013.
56. Siegel RL, Ward EM, Jemal A,. Trends in colorectal cancer incidence rates in the United States by tumor location and stage, 1992-2008. Cancer Epidemiol Biomarkers Prev. 2012; 21: 411-416.
57. Lansdorp-Vogelaar I, Kuntz KM, Knudsen AB, van Ballegooijen M, Zauber AG, Jemal A,. Contribution of screening and survival differences to racial disparities in colorectal cancer rates. Cancer Epidemiol Biomarkers Prev. 2012; 21: 728-736.
58. Siegel RL, Jemal A, Thun MJ, Hao Y, Ward EM,. Trends in the incidence of colorectal cancer in relation to county-level poverty among blacks and whites. J Natl Med Assoc. 2008; 100: 1441-1444.
59. Edwards BK, Ward E, Kohler BA, et al. Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer. 2010; 116: 544-573.
60. Soneji S, Iyer SS, Armstrong K, Asch DA,. Racial disparities in stage-specific colorectal cancer mortality: 1960-2005. Am J Public Health. 2010; 100: 1912-1916.
61. Wang A, Clouston SA, Rubin MS, Colen CG, Link BG,. Fundamental causes of colorectal cancer mortality: the implications of informational diffusion. Milbank Q. 2012; 90: 592-618.
62. Robbins AS, Siegel RL, Jemal A,. Racial disparities in stage-specific colorectal cancer mortality rates from 1985 to 2008. J Clin Oncol. 2012; 30: 401-405.
63. Singh GK, Miller BA, Hankey BF,. Changing area socioeconomic patterns in U.S. cancer mortality, 1950-1998: Part II-Lung and colorectal cancers. J Natl Cancer Inst. 2002; 94: 916-925.
64. Blot WJ, Fraumeni JF Jr, Stone BJ, McKay FW,. Geographic patterns of large bowel cancer in the United States. J Natl Cancer Inst. 1976; 57: 1225-1231.
65. Naishadham D, Lansdorp-Vogelaar I, Siegel R, Cokkinides V, Jemal A,. State disparities in colorectal cancer mortality patterns in the United States. Cancer Epidemiol Biomarkers Prev. 2011; 20: 1296-1302.
66. Siegel R, DeSantis C, Virgo K, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 2012; 62: 220-241.
67. Chu KC, Tarone RE, Chow WH, Hankey BF, Ries LAG,. Temporal patterns in colorectal cancer incidence, survival, and mortality from 1950 through 1990. J Natl Cancer Inst. 1994; 86: 997-1006.
68. Gross CP, Andersen MS, Krumholz HM, McAvay GJ, Proctor D, Tinetti ME,. Relation between Medicare screening reimbursement and stage at diagnosis for older patients with colon cancer. JAMA. 2006; 296: 2815-2822.
69. Moertel CG, Fleming TR, Macdonald JS, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med. 1990; 322: 352-358.
70. NIH consensus conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA. 1990; 264: 1444-1450.
71. Andre T, Boni C, Mounedji-Boudiaf L, et al. Multicenter International Study of Oxaliplatin/5-Fluorouracil-Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004; 350: 2343-2351.
72. Wolmark N, Rockette H, Mamounas E, et al. Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes' B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C-04. J Clin Oncol. 1999; 17: 3553-3559.
73. Curley SA, Izzo F, Delrio P, et al. Radiofrequency ablation of unresectable primary and metastatic hepatic malignancies: results in 123 patients. Ann Surg. 1999; 230: 1-8.
74. Hughes KS, Simon R, Songhorabodi S, et al. Resection of the liver for colorectal carcinoma metastases: a multi-institutional study of patterns of recurrence. Surgery. 1986; 100: 278-284.
75. Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008; 26: 2013-2019.
76. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med. 2000; 343: 905-914.
77. Wiering B, Krabbe PF, Jager GJ, Oyen WJ, Ruers TJ,. The impact of fluor-18-deoxyglucose-positron emission tomography in the management of colorectal liver metastases. Cancer. 2005; 104: 2658-2670.
78. Wineshaw HM, Robbins AS, Jemal A,. Disparities in survival improvement for metastatic colorectal cancer by race/ethnicity and age in the United States [published online ahead of print January 21, 2014]. Cancer Causes Control.
79. Grubbs SS, Polite BN, Carney J Jr, et al. Eliminating racial disparities in colorectal cancer in the real world: it took a village. J Clin Oncol. 2013; 31: 1928-1930.
80. Centers for Disease Control and Prevention, Division of Cancer Prevention and Control. Colorectal Cancer Control Program (CRCCP) Fact Sheet. cdc.gov/cancer/crccp/pdf/CRCCP-FactSheet.pdf. Accessed December 2, 2013.